Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Photodynamic oncolytic virus therapy for central nervous system malignancies

ABSTRACT: Photodynamic oncolytic virus therapy for central nervous system malignancies

PROVIDER: PRJNA923791 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR23080723_1.fastq.gz	Fastqsanger.gz
	SRR23080723_2.fastq.gz	Fastqsanger.gz
	SRR23080724_1.fastq.gz	Fastqsanger.gz
	SRR23080724_2.fastq.gz	Fastqsanger.gz
	SRR23080725_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 48

Similar Datasets

Photodynamic oncolytic virus therapy for central nervous system malignancies

Project description:The goal of the study was to determine whether photodynamic oncolytic virus therapy of glioblastoma and malignant meningioma xenografts in mice alters transciptomics associated with efficacy. RNA sequencing was used from tumors treated with PBS, laser, G47delta-KillerRed, and G47delta-KillerRed and laser, which is photodynamic oncolytic virus therapy.

2023-01-18 | GSE222895 | GEO

A tumor-associated photoreceptor signature unifies distinct central nervous system malignancies

Project description:A tumor-associated photoreceptor signature unifies distinct central nervous system malignancies

| PRJNA1150226 | ENA

Photodynamic augmentation of oncolytic virus therapy for central nervous system malignancies.

Project description:Oncolytic viruses (OVs) have emerged as a clinical therapeutic modality potentially effective for cancers that evade conventional therapies, including central nervous system malignancies. Rationally designed combinatorial strategies can augment the efficacy of OVs by boosting tumor-selective cytotoxicity and modulating the tumor microenvironment (TME). Photodynamic therapy (PDT) of cancer not only mediates direct neoplastic cell death but also primes the TME to sensitize the tumor to secondary therapies, allowing for the combination of two potentially synergistic therapies with broader targets. Here, we created G47Δ-KR, clinical oncolytic herpes simplex virus G47Δ that expresses photosensitizer protein KillerRed (KR). Optical properties and cytotoxic effects of G47Δ-KR infection followed by amber LED illumination (peak wavelength: 585-595 nm) were examined in human glioblastoma (GBM) and malignant meningioma (MM) models in vitro. G47Δ-KR infection of tumor cells mediated KR expression that was activated by LED and produced reactive oxygen species, leading to cell death that was more robust than G47Δ-KR without light. In vivo, we tested photodynamic-oncolytic virus (PD-OV) therapy employing intratumoral injection of G47Δ-KR followed by laser light tumor irradiation (wavelength: 585 nm) in GBM and MM xenografts. PD-OV therapy was feasible in these models and resulted in potent anti-tumor effects that were superior to G47Δ-KR alone (without laser light) or laser light alone. RNA sequencing analysis of post-treatment tumor samples revealed PD-OV therapy-induced increases in TME infiltration of variable immune cell types. This study thus demonstrated the proof-of-concept that G47Δ-KR enables PD-OV therapy for neuro-oncological malignancies and warrants further research to advance potential clinical translation.

| S-EPMC10529118 | biostudies-literature

A tumor-associated photoreceptor signature unifies distinct central nervous system malignancies [Methylation array]

Project description:A tumor-associated photoreceptor signature unifies distinct central nervous system malignancies [Methylation array]

| PRJNA1377649 | ENA

A tumor-associated photoreceptor signature unifies distinct central nervous system malignancies [ATAC-seq]

Project description:A tumor-associated photoreceptor signature unifies distinct central nervous system malignancies [ATAC-seq]

| PRJNA1416951 | ENA

A tumor-associated photoreceptor signature unifies distinct central nervous system malignancies [scRNA-seq]

Project description:A tumor-associated photoreceptor signature unifies distinct central nervous system malignancies [scRNA-seq]

| PRJNA1141927 | ENA

A tumor-associated photoreceptor signature unifies distinct central nervous system malignancies [bulkRNA-seq]

Project description:A tumor-associated photoreceptor signature unifies distinct central nervous system malignancies [bulkRNA-seq]

| PRJNA1150229 | ENA

Iodine I 131 Monoclonal Antibody 3F8 in Treating Patients With Central Nervous System Cancer or Leptomeningeal Cancer

Project description:RATIONALE: Radiolabeled monoclonal antibodies, such as iodine I 131 monoclonal antibody 3F8, can find tumor cells and carry tumor-killing substances to them without harming normal cells. This may be an effective treatment for central nervous system cancer or leptomeningeal metastases. PURPOSE: This phase II trial is studying the side effects and how well iodine I 131 monoclonal antibody 3F8 works in treating patients with central nervous system cancer or leptomeningeal cancer.

| 2037925 | ecrin-mdr-crc

A tumor-associated photoreceptor signature unifies distinct central nervous system malignancies [ATAC-seq]

Project description:Pineoblastoma is a clinically aggressive childhood brain tumor composed of distinct molecular subgroups with divergent driver genes, demographics, and clinical outcomes. To identify developmental origins and mechanisms governing disease pathogenesis, we derive single-cell transcriptomes from pineal parenchymal tumors, aligning malignant cells with developmental counterparts to retrace cellular origins. Integrative computational analyses map pineoblastoma origins to transient, cycling pinealocyte progenitors during development. Lineage-specific perturbation of suspected drivers in the early pineal gland yields preclinical models representative of consensus molecular subgroups. Multi-omic characterization of patient tumors and these models uncovers a tumor-associated photoreceptor signature (TAPS) common to pineoblastoma, retinoblastoma, and Group 3 medulloblastoma. Transcriptional activity of this signature within respective cellular origins establishes a developmental basis for molecular similarities between entities. Photoreceptor signature constituents are selective dependencies across these anatomically distinct central nervous system malignancies, motivating future studies evaluating developmentally encoded programs of malignancy as potential therapeutic liabilities.

2026-02-07 | GSE318234 | GEO

Efavirenz Central Nervous System Side Effects

Project description:Efavirenz Central Nervous System Side Effects

| PRJNA354669 | ENA